Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Three-Part, Phase 1a Dose Escalation Clinical Trial to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-622 in Healthy Participants

NCT06650761 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT06650761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06650761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Three-Part, Phase 1a Dose Escalation Clinical Trial to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-622 in Healthy Participants
Lead sponsor
Celldex Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
November 1, 2024
Completion date
April 24, 2026
Enrollment
85 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants